CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ±è¹Ì³ª
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °£Àå, °£¾Ï
  • Á÷ À§: Á¶±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

µî·Ï

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ ´Ù¿î·Îµå
10 ÇØ¿Ü Kim MN (1ÀúÀÚ), Ro SW, Kim DY, Dim DY, Cho KJ, Park JH, Lim HY, Han KH. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology 2015. Aug;76(2):257-67.  
9 ÇØ¿Ü Kim JH, Kim MN (°øµ¿ 1ÀúÀÚ), Han KH, Kim SU. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int 2015 Apr;35(4):1103-15.  
8 ÇØ¿Ü Kim MN (1ÀúÀÚ), Han KH, Ahn SH. Prevention of Hepatocellular Carcinoma: Beyond Hepatitis B Vaccination. Seminars in Oncology 2015 Apr;42(2):316-28.  
7 ÇØ¿Ü Kim MN (1ÀúÀÚ), Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, Han KH. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. Liver Int 2014;34:1216-1223.  
6 ÇØ¿Ü Kim MN (1ÀúÀÚ), Kim BK, Han KH, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol 2014:1-14.  
5 ÇØ¿Ü Kim MN (1ÀúÀÚ), Lee CK, Ahn SH, Lee S, Kim SU, Kim do Y, Kim HS, Han KH, Chon CY, Park JY. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014;34:1543-1549.  
4 ÇØ¿Ü Kim MN (1ÀúÀÚ), Kim SU, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH. Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir. J Clin Gastroenterol 2014;48:272-278.  
3 ÇØ¿Ü Kim MN (1ÀúÀÚ), Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681-688.  
2 ÇØ¿Ü Kim MN (1ÀúÀÚ), Kim HK, Shim CN, Lee HJ, Lee H, Park JC, Shin SK, Lee SK, Lee YC. Tumour size is related to the curability of signet ring cell early gastric cancer with endoscopic submucosal dissection: a retrospective single centre study. Dig Liver Dis 2014;46:898-902.  
1 ±¹³» Kim MN (1ÀúÀÚ), Yoon KT, Park JY, Kim do Y, Ahn SH, Chon CY, Han KH. [A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C]. Korean J Hepatol 2009;15:496-503.  
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729